Jay Guan, MD
Gastroenterology · Los Angeles, CANPI 1295122497
Payments from drug & device makers
Across 461 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$1K
- Madrigal Pharmaceuticals$542
- Ovesco Endoscopy USA, Inc.$529
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$514
- Lilly USA, LLC$469
- plus $4K from 25 others
What the payments were for
- Travel & lodging$5295%
- Food & beverage$9,74392%
- Education$2653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 184 | $3,476 |
| Johnson & Johnson(2 entities) | 33 | $1,177 |
| Madrigal Pharmaceuticals | 31 | $542 |
| Ovesco Endoscopy USA, Inc. | 1 | $529 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $514 |
| Lilly USA, LLC | 23 | $469 |
| Pfizer | 24 | $463 |
| Sanofi | 16 | $402 |
| Endogastric Solutions, Inc | 7 | $383 |
| Bristol Myers Squibb | 17 | $291 |
| Regeneron Healthcare Solutions, Inc. | 12 | $288 |
| Aimmune Therapeutics, Inc. | 11 | $287 |
| Ardelyx, Inc. | 10 | $253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $202 |
| Apollo Endosurgery US Inc | 4 | $160 |
| Novo Nordisk | 7 | $146 |
| Gilead | 7 | $145 |
| Ironwood Pharmaceuticals, Inc | 7 | $140 |
| Ferring Pharmaceuticals Inc. | 7 | $139 |
| Intercept Pharmaceuticals, Inc. | 5 | $96 |
| Phathom Pharmaceuticals, Inc. | 3 | $82 |
| Evoke Pharma, Inc. | 3 | $66 |
| Nestle Healthcare Nutrition Inc. | 3 | $57 |
| Lucid Diagnostics Inc. | 2 | $41 |
| Merck | 2 | $34 |
| Celltrion USA Inc. | 2 | $34 |
| Digestive Care, Inc. | 1 | $30 |
| QOL Medical, LLC | 1 | $30 |
| Exact Sciences | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,537 in reported general payments places this provider in the 75th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 17 | $334,360 |
| CreonLipase/Protease/Amylase | 37 | $113,481 |
| LinzessLinaclotide | 98 | $109,207 |
| Humira(Cf) PenAdalimumab | 15 | $100,442 |
| XifaxanRifaximin | 36 | $93,797 |
| RezdiffraResmetirom | 13 | $60,859 |
| ViberziEluxadoline | 18 | $27,652 |
| OzempicSemaglutide | 27 | $26,746 |
| Mesalamine | 22 | $17,272 |
| MotegrityPrucalopride Succinate | 18 | $12,483 |
| Budesonide EcBudesonide | 31 | $8,710 |
| Omeprazole | 309 | $5,813 |
| Colesevelam Hcl | 49 | $4,858 |
| Lubiprostone | 24 | $4,568 |
| Esomeprazole Magnesium | 18 | $3,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,177 | $334,36017 claims |
| AbbVieCreon, Linzess, Viberzi | $3,476 | $250,340153 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $514 | $93,79736 claims |
| Madrigal PharmaceuticalsRezdiffra | $542 | $60,85913 claims |
| Novo NordiskOzempic | $146 | $26,74627 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $202 | $12,48318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Los Angeles
- Gil MelmedLos Angeles$3M
- Bennett RothLos Angeles$2.8M
- Sammy SaabLos Angeles$2M
- Caroline HwangLos Angeles$908K
- Andres YarurLos Angeles$903K
- Brennan SpiegelLos Angeles$845K
- Nicholas KaryotakisLos Angeles$710K
- Venkataraman MuthusamyLos Angeles$693K
- Sadeea AbbasiLos Angeles$556K
- Peter WinkleCypress$116.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.